CareDx Study Links Elevated AlloSure Kidney Levels to Nearly Threefold Higher Risk of Adverse Graft Outcomes
PUBT · 3d ago
Share
Listen to the news
- CareDx is presenting AlloSure Kidney study results at ASN Kidney Week in Denver, October 22-25, 2026.
- Elevated AlloSure Kidney levels were associated with greater risk of graft loss or declining kidney function in patients with borderline rejection or T-cell-mediated rejection.
- An independent randomized trial found AlloSure-based monitoring reduced kidney transplant biopsies while maintaining similar clinical outcomes.
- A multinational validation study found AlloSure Kidney and AlloSure Plus maintained strong rejection prediction under updated Banff 2024 pathology criteria.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610220705BIZWIRE_USPR_____20261022_BW386659) on October 22, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending